https://orcid.org/0000-0003-1803-2046
Citations (40)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Luca Stingeni, Giovanna Malara, Andrea Conti, Luisa Di Costanzo, Carlo Giovanni Carrera, Martina Burlando, Piergiorgio Malagoli, Maria Letizia Musumeci, Federico Bardazzi, Valeria Brazzelli, Paolo Amerio, Clara De Simone, Sara Trevisini, Anna Balato, Matteo Megna, Francesco Loconsole, Catia De Felice, Marta Bartezaghi, Alice Rausa, Elisabetta Aloisi, Roberto Orsenigo & Antonio Costanzo. (2023) Efficacy of Secukinumab in Psoriasis: Post Hoc Gender-Wise Analysis of the SUPREME Study. Clinical, Cosmetic and Investigational Dermatology 16, pages 27-38.
Read now
Read now
Stefano Dastoli, Maria Passante, Francesco Loconsole, Edoardo Mortato, Anna Balato, Vincenzo Piccolo, Claudio Guarneri, Laura Macca, Eugenio Provenzano, Giancarlo Valenti, Domenico D’Amico, Giuseppe Micali, Maria Letizia Musumeci, Giovanni Palazzo, Caterina Foti, Paolo Romita, Gabriella Fabbrocini, Matteo Megna, Ilaria Sammarra, Luigi Bennardo & Cataldo Patruno. (2023) Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy. Journal of Dermatological Treatment 34:1.
Read now
Read now
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, Yuda Chongpison & Pravit Asawanonda. (2022) On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study. Journal of Dermatological Treatment 33:7, pages 2963-2974.
Read now
Read now
Francesco Messina & Stefano Piaserico. (2022) The dark side of the moon: the immune-mediated adverse events of IL-17A/IL-17R inhibition. Journal of Dermatological Treatment 33:5, pages 2443-2454.
Read now
Read now
Fatma Elif Yıldırım & Fatma Aslı Hapa. (2022) Clinical efficacy and safety of secukinumab for psoriasis in a real-world setting in Turkey. Journal of Dermatological Treatment 33:3, pages 1531-1537.
Read now
Read now
Bénédicte Caron, Jean-Yves Jouzeau, Pierre Miossec, Nadine Petitpain, Pierre Gillet, Patrick Netter & Laurent Peyrin-Biroulet. (2022) Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opinion on Drug Safety 21:2, pages 223-239.
Read now
Read now
Andrea Chiricozzi, Anna Balato, Curdin Conrad, Andrea Conti, Paolo Dapavo, Paulo Ferreira, Francesca Maria Gaiani, Luiz Leite, Piergiorgio Malagoli, Pedro Mendes-Bastos, Matteo Megna, Francesco Messina, Alessia Nidegger, Giulia Odorici, Salvatore Panduri, Stefano Piaserico, Leonardo Piscitelli, Francesca Prignano, Simone Ribero, Joana Valerio & Tiago Torres. (2020) Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Journal of Dermatological Treatment 31:5, pages 476-483.
Read now
Read now
S. D’Adamio, D. Silvaggio, P. Lombardo, L. Bianchi, M. Talamonti & M. Galluzzo. (2019) The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis. Expert Opinion on Drug Safety 18:11, pages 1031-1041.
Read now
Read now
Articles from other publishers (32)
Nikolai Loft, Alexander Egeberg, Daniel Isufi, Mads K. Rasmussen, Lars E. Bryld, Tomas N. Dam, Kawa K. Ajgeiy, Trine Bertelsen & Lone Skov. (2023) Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study. Acta Dermato-Venereologica 103, pages adv12616.
Crossref
Crossref
Yangfeng Ding, Wei Li, Xin Guan, Na Liu, Ying Zhou, Gaojie Li, Xiaohua Wang, Zhidong Wang, Xiao Xiao, Bin Yang, Chengzhi Lv, Chunlei Zhang & Yuling Shi. (2023)
Treatment outcomes of secukinumab in adult patients with
moderate‐to‐severe
plaque psoriasis in China: A real‐world multicenter retrospective study
. Clinical and Translational Science 16:10, pages 1803-1814.
Crossref
Crossref
Hao Trong Nguyen, Nhi Thi Uyen Pham, Tu Nguyen Anh Tran, Nguyen Nhat Pham, Yen Thi Bui & Thao Thi Phuong Vu. (2022) Long-Term Effectiveness and Drug Survival of Secukinumab in Vietnamese Patients with Psoriasis: Results from a Retrospective ENHANCE Study. Dermatology and Therapy 13:2, pages 465-476.
Crossref
Crossref
Kim A. Papp, Melinda Gooderham, Ignacio Dei-Cas, Adriana LopezTello, Juan C. Garcia-Rodriguez, Carmen Yris Taveras, Azucena Hernández Rousselin, Alberto Lavieri, Mónica Maiolino, Delfina Guadalupe Villanueva Quintero, Lenka Rihakova, Mariano Salibe & Wilfran Pertuz. (2022) Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatology and Therapy 13:1, pages 269-283.
Crossref
Crossref
Pablo Chicharro, Mar Llamas‐Velasco, Susana Armesto, Enrique Herrera Acosta, David Vidal, Eva Vilarrasa, Raquel Rivera‐Diaz, Pablo De‐la‐Cueva, Antonio Martorell‐Calatayud, Ferran Ballescà, Isabel Belinchon, Gregorio Carretero, Lourdes Rodriguez, Alberto Romero‐Maté, Josep Pujol‐Montcusí, Laura Salgado, Antonio Sahuquillo‐Torralba, Pablo Coto‐Segura, Ofelia Baniandrés Rodríguez, Rosa Feltes, José Riera‐Monroig & Esteban Dauden. (2022) Secukinumab is effective and safe in the long‐term treatment of plaque psoriasis in a daily practice setting: Multicenter study in 384 Spanish patients. Dermatologic Therapy 35:12.
Crossref
Crossref
Xi‐Bei Chen, Yu‐Xin Zheng, Li‐Ran Ye, Xue‐Yan Chen & Xiao‐Yong Man. (2022) Gradually increasing the dosing interval of Secukinumab for moderate to severe plaque psoriasis: A single‐center, uncontrolled, prospective study in 36 weeks. Dermatologic Therapy 35:12.
Crossref
Crossref
Cristina Pellegrini, Maria Esposito, Ernesto Rossi, Paolo Gisondi, Stefano Piaserico, Paolo Dapavo, Andrea Conti, Alessio Gambardella, Martina Burlando, Alessandra Narcisi, Annamaria Offidani, Riccardo Balestri, Federico Bardazzi, Francesca Prignano, Cristina Mugheddu, Marco Romanelli, Giovanna Malara, Giovanni Schinzari & Maria Concetta Fargnoli. (2022) Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. Dermatology and Therapy 12:11, pages 2613-2626.
Crossref
Crossref
Diamant Thaçi, Sascha Gerdes, Kristian Gaarn Du Jardin, Jean-Luc Perrot & Lluís Puig. (2022) Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy 12:10, pages 2325-2341.
Crossref
Crossref
Vincent T Ma, Christopher D Lao, Leslie A Fecher & Elena Schiopu. (2022) Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy 14:8, pages 593-598.
Crossref
Crossref
Bruce Strober, Dhaval Patil, Robert R. McLean, Melissa Moore-Clingenpeel, Ning Guo, Eugenia Levi & Mark Lebwohl. (2022) Utilization Trends and Impact of Secukinumab Treatment on Clinical Outcomes in Biologic-Naive Patients with Psoriasis in a US Real-World Setting. Dermatology and Therapy 12:6, pages 1351-1365.
Crossref
Crossref
Bardur Sigurgeirsson, John Browning, Stephen Tyring, Jacek C. Szepietowski, Raquel Rivera‐Díaz, Isaak Effendy, Deborah Keefe, Gerard Bruin, Bertrand Paguet, Rong Fu, Isabelle Hampele, Maximilian Reinhardt & Manmath Patekar. (2022) Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52‐week results from MATURE, a randomized, placebo‐controlled trial. Dermatologic Therapy 35:3.
Crossref
Crossref
Delia Colombo, Luca Bianchi, Gabriella Fabbrocini, Salvatore Corrao, Annamaria Offidani, Luca Stingeni, Antonio Costanzo, Giovanni Pellacani, Ketty Peris, Federico Bardazzi, Giuseppe Argenziano, Silvana Ruffolo, Paolo Dapavo, Carlo Carrera, Maria Concetta Fargnoli, Aurora Parodi, Marco Romanelli, Piergiorgio Malagoli, Marina Talamonti, Matteo Megna, Massimo Raspanti, Matteo Paolinelli, Katharina Hansel, Alessandra Narcisi, Andrea Conti, Clara De Simone, Marco Adriano Chessa, Alina De Rosa, Eugenio Provenzano, Michela Ortoncelli, Chiara Moltrasio, Rosaria Fidanza, Martina Burlando, Annalisa Tonini, Francesca Maria Gaiani, Lucia Simoni, Alessandra Ori, Martina Fiocchi & Emanuela Zagni. (2021)
Real‐world evidence of biologic treatments in moderate–severe psoriasis in Italy: Results of the
CANOVA
(
EffeCtiveness
of biologic
treAtmeNts
for plaque
psOriasis
in Italy: An
obserVAtional
longitudinal study of real‐life clinical practice) study
. Dermatologic Therapy 35:1.
Crossref
Crossref
Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. McInnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, José M. Carballido, Peter Häusermann, Claudio Calonder, Beate Vogel, Jean-Michel Rondeau & Gerard Bruin. (2022) Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & Therapeutics 229, pages 107925.
Crossref
Crossref
Stefania Nicola, Silvia Gallo Cassarino, Giovanni Rolla, Giada Geronazzo, Monica Fornero & Luisa Brussino. (2022) Three years of methotrexate and secukinumab: Outcomes of psoriatic arthritis in a real-life setting. Journal of the American Academy of Dermatology 86:1, pages 241-243.
Crossref
Crossref
Cristina Galache Osuna, Sebastián Reyes García, Jimena Carrero Martín, Virginia García Jiménez, Francisco Vázquez López & Jorge Santos-Juanes. (2021) Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World. Life 11:12, pages 1348.
Crossref
Crossref
Carmen RODRÍGUEZ-CERDEIRA, José L. GONZÁLEZ-CESPÓN, Erick MARTÍNEZ-HERRERA, Miguel CARNERO-GREGORIO, Adriana LÓPEZ-BARCENAS, Alexey SERGEEV & Ditte M. SAUNTE. (2021) Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Italian Journal of Dermatology and Venereology 156:5.
Crossref
Crossref
Nikolai Loft, Anne Bregnhøj, Simon Fage, Claus Henrik Nielsen, Christian Enevold, Claus Zachariae, Lars Iversen & Lone Skov. (2021)
Effectiveness of brodalumab after previous treatment failure of interleukin‐
17A
inhibitors in patients with psoriasis
. Dermatologic Therapy 34:6.
Crossref
Crossref
M. Lebwohl, A. Deodhar, C.E.M. Griffiths, M.A. Menter, D. Poddubnyy, W. Bao, V. Jehl, K. Marfo, P. Primatesta, A. Shete, V. Trivedi & P.J. Mease. (2021) The risk of malignancy in patients with secukinumab‐treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow‐up. British Journal of Dermatology 185:5, pages 935-944.
Crossref
Crossref
Paolo Gisondi, Francesco Loconsole, Paola Raimondo & Roberto Ravasio. (2021) Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy. Global & Regional Health Technology Assessment 8, pages 120-130.
Crossref
Crossref
Paulo Ferreira & Pedro Mendes‐Bastos. (2021) Secukinumab: A complete approach to psoriatic patients—Real‐world evidence study. Dermatologic Therapy 34:2.
Crossref
Crossref
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck & Robert Sabat. (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. The Lancet 397:10275, pages 754-766.
Crossref
Crossref
Manuela Ceccarelli, Emmanuele Venanzi Rullo, Massimiliano Berretta, Bruno Cacopardo, Giovanni Francesco Pellicanò, Giuseppe Nunnari & Claudio Guarneri. (2020) New generation biologics for the treatment of psoriasis and psoriatic arthritis. State of the art and considerations about the risk of infection. Dermatologic Therapy 34:1.
Crossref
Crossref
Claudio Bonifati, Aldo Morrone, Antonio Cristaudo & Dario Graceffa. (2020) Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience. Dermatologic Therapy 34:1.
Crossref
Crossref
Cheng Xu, Jie Ji, Ting Su, Hong-Wei Wang & Zhong-Lan Su. (2021) The Association of Psoriasis and Obesity: Focusing on IL-17A-Related Immunological Mechanisms. International Journal of Dermatology and Venereology 4:2, pages 116-121.
Crossref
Crossref
Nikolai Loft, Anne-Sofie Halling, Alexander Egeberg & Lone Skov. (2021) Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 84:1, pages 130-138.
Crossref
Crossref
Matteo Megna, Gabriella Fabbrocini, Maria Ferrillo & Eleonora Cinelli. (2020) Erythrodermic psoriasis successfully and rapidly treated with brodalumab: Report of two cases. Dermatologic Therapy 33:6.
Crossref
Crossref
Antonio Carpentieri, Paola Mascia, Marco Fornaro, Marie Beylot‐Barry, Alain Taieb, Caterina Foti & Francesco Loconsole. (2020) Effectiveness and safety of secukinumab in patients with moderate‐severe psoriasis: A multicenter real‐life study. Dermatologic Therapy 33:6.
Crossref
Crossref
N. Rompoti, P. Sidiropoulou, P. Panagakis, A. Stratigos, M. Papoutsaki, E. Stefanaki, C. Vavouli, M. Politou, A. Befon, P. Kostakis, D. Rigopoulos & E. Nicolaidou. (2020) Real‐world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response. Journal of the European Academy of Dermatology and Venereology 34:6, pages 1240-1247.
Crossref
Crossref
M. Augustin, D. Jullien, A. Martin & C. Peralta. (2020) Real‐world evidence of secukinumab in psoriasis treatment – a meta‐analysis of 43 studies. Journal of the European Academy of Dermatology and Venereology 34:6, pages 1174-1185.
Crossref
Crossref
K. Reich, R.B. Warren, L.C. Coates & G. Di Comite. (2020) Long‐term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. Journal of the European Academy of Dermatology and Venereology 34:6, pages 1161-1173.
Crossref
Crossref
Jashin J. Wu, Joseph F. Merola, Steven R. Feldman, Alan Menter & Mark Lebwohl. (2020) Treatment of Psoriasis with Secukinumab in Challenging Patient Scenarios: A Review of the Available Evidence. Dermatology and Therapy 10:3, pages 351-364.
Crossref
Crossref
Hsuan Ning Wang & Yu Huei Huang. (2020) Changes in metabolic parameters in psoriatic patients treated with secukinumab. Therapeutic Advances in Chronic Disease 11, pages 204062232094477.
Crossref
Crossref